[Skip to Content]
[Skip to Content Landing]
Views 2,679
Citations 0
News From the Food and Drug Administration
October 15, 2019

First Treatment for Lung Disease Related to Scleroderma

JAMA. 2019;322(15):1442. doi:10.1001/jama.2019.16349

Nintedanib has received an expanded indication to include interstitial lung disease (ILD) that’s associated with scleroderma—a rare autoimmune disorder that causes abnormal connective tissue growth throughout the body. Nintedanib is the first therapy approved for adults with this rare lung condition. It was approved in 2014 to treat idiopathic pulmonary fibrosis, another interstitial lung disease.